home / stock / biib / biib articles

BIIB Articles, Biogen Inc. - From 02/14/24

Stock Information
Company Name: Biogen Inc.
Stock Symbol: BIIB
Market: NASDAQ
Website: biogen.com
Menu
BIIB BIIB Quote BIIB Short BIIB News BIIB Articles BIIB Message Board
Get BIIB Alerts

News, Short Squeeze, Breakout and More Instantly...
Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says | Benzinga

Tuesday, Biogen Inc (NASDAQ:BIIB) posted fourth-quarter 2023 sales of $2.39 billion, missing the consensus of $2.46 billion, down 6% Y/Y ...
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday | Benzinga

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...

Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday? | Benzinga

Wall Street witnessed one of the worst sessions since the beginning of the year, with widespread declines across the board as stocks were hit by th...

Why Is Biogen Stock Trading Lower On Tuesday? | Benzinga

On Tuesday, Biogen Inc (NASDAQ:BIIB) posted fourth-quarter 2023 sales of $2.39 billion, missing the consensus of $2.46 billion, down 6% Y...
Nasdaq, S&P 500 Set For Weaker Open As Traders Keep Eyes Peeled On Inflation Data: Analyst Flags Key CPI Report Item To Watch | Benzinga

Wall Street is poised to open in the red on Tuesday as stock futures declined ahead of the all-important consumer price inflation report for Janu...

Here's How Much You Would Have Made Owning Biogen Stock In The Last 20 Years | Benzinga

Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 1.7% on an annualized basis producing an average annual return of 9.28%....

Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines | Benzinga

Biogen Inc (NASDAQ:BIIB) is pulling the plug on its Aduhelm Alzheimer’s disease drug more than two years after the drug came into the limeli...
AT&T To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday | Benzinga

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...

Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts | Benzinga

UBS has downgraded Biogen Inc (NASDAQ:BIIB), noting inflection for its second Alzheimer’s drug Leqembi (lecanemab) will take l...

Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns | Benzinga

A new era in Alzheimer’s diagnosis is on the horizon as Dr. Suzanne Schindler and her team at Washington University School of Medic...
Previous 10 Next 10